Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.

There was a nonsignificant trend toward an improved OS (16.6 months vs 13.3 months, HR 0.85, 95% CI 0.66–1.08, P <0.174); however, the true effect of bevacizumab on OS is obscured and likely diluted by a 40% crossover to bevacizumab monotherapy among patients in the chemotherapy arm at the time of disease progression.

also in 5,406 other papers